Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial
17M new shares and pre-funded warrants bring Altimmune about $75M in gross proceeds to back its planned Phase 3 MASH trial and other needs.
www.stocktitan.netI don’t have live access to up-to-the-minute news right now. Based on recent public signals, here’s what’s circulating about LOOKSMAXXER - ALT and related topics:
If you want, I can:
Would you like me to tighten the search to LOOKSMAXXER mentions or focus on confirmed ALT developments with reliable sources? I can also prepare a concise timeline of ALT-related milestones from 2026 sources with citations.
17M new shares and pre-funded warrants bring Altimmune about $75M in gross proceeds to back its planned Phase 3 MASH trial and other needs.
www.stocktitan.netTrack the latest AltLayer price, market cap, trading volume, news and more with CoinGecko's live ALT price chart and popular cryptocurrency price tracker.
www.coingecko.comAltimmune plans to raise $75 million via a direct offering to bankroll its Phase 3 MASH trial, easing near-term funding risk.
stocktwits.com